Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Fortress Biotech (FBIO) Cost of Revenue: 2016-2025

Historic Cost of Revenue for Fortress Biotech (FBIO) over the last 10 years, with Sep 2025 value amounting to $5.8 million.

  • Fortress Biotech's Cost of Revenue rose 28.72% to $5.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.2 million, marking a year-over-year increase of 9.30%. This contributed to the annual value of $20.9 million for FY2024, which is 8.80% down from last year.
  • Fortress Biotech's Cost of Revenue amounted to $5.8 million in Q3 2025, which was up 16.52% from $4.9 million recorded in Q2 2025.
  • In the past 5 years, Fortress Biotech's Cost of Revenue ranged from a high of $11.2 million in Q3 2021 and a low of $2.2 million during Q4 2023.
  • For the 3-year period, Fortress Biotech's Cost of Revenue averaged around $5.4 million, with its median value being $5.7 million (2024).
  • In the last 5 years, Fortress Biotech's Cost of Revenue soared by 230.48% in 2021 and then crashed by 70.87% in 2023.
  • Fortress Biotech's Cost of Revenue (Quarterly) stood at $9.5 million in 2021, then fell by 18.97% to $7.7 million in 2022, then plummeted by 70.87% to $2.2 million in 2023, then soared by 108.19% to $4.7 million in 2024, then increased by 28.72% to $5.8 million in 2025.
  • Its Cost of Revenue was $5.8 million in Q3 2025, compared to $4.9 million in Q2 2025 and $4.8 million in Q1 2025.